PC
AVDL

PointState Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

PointState Capital’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-400,000
Closed -$5.72M – 116
2014
Q3 		$5.72M Buy
+400,000
New +$5.75M 0.1% 71

Other funds holding AVDL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CM
Castleark Management Chicago, Illinois $3.02B AUM 53.92% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

PointState Capital's AVDL Position: Q4 2014 in Review

PointState Capital sold out of Avadel Pharmaceuticals (AVDL) in Q4 2014, closing a stake of 400,000 shares — an estimated $5.72M sold.

PointState Capital first reported a position in AVDL in Q3 2014 and held it in 1 quarter. The position peaked at $5.72M in Q3 2014. 94 funds tracked by Wall St. Rank hold AVDL as of Q4 2014.

  • PointState Capital reported no remaining Avadel Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • PointState Capital sold 400,000 Avadel Pharmaceuticals shares in Q4 2014, an estimated $5.72M.
  • PointState Capital first reported a position in Avadel Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • PointState Capital's Avadel Pharmaceuticals position peaked at $5.72M in Q3 2014.
  • 94 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2014.

Based on PointState Capital's 13F filing for Q4 2014, filed 17 Feb 2015.